SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yongda Zhang, Bruce Z. Lu, Guisheng Li, Sonia Rodriguez, Jonathan Tan, Han-Xun Wei, Jianxiu Liu, Frank Roschangar, Fei Ding, Wenyi Zhao, Bo Qu, Diana Reeves, Nelu Grinberg, Heewon Lee, Golo Heckmann, Oliver Niemeier, Michael Brenner, Youla Tsantrizos, Pierre L. Beaulieu, Azad Hossain, Nathan Yee, Vittorio Farina, Chris H. Senanayake, A Highly Concise and Convergent Synthesis of HCV Polymerase Inhibitor Deleobuvir (BI 207127): Application of a One-Pot Borylation–Suzuki Coupling Reaction, Organic Letters, 2014, 16, 17, 4558

    CrossRef

  2. 2
    Fred Poordad, Christophe Hezode, Roger Trinh, Kris V. Kowdley, Stefan Zeuzem, Kosh Agarwal, Mitchell L. Shiffman, Heiner Wedemeyer, Thomas Berg, Eric M. Yoshida, Xavier Forns, Sandra S. Lovell, Barbara Da Silva-Tillmann, Christine A. Collins, Andrew L. Campbell, Thomas Podsadecki, Barry Bernstein, ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis, New England Journal of Medicine, 2014, 370, 21, 1973

    CrossRef

  3. 3
    C Hutchison, A Kwong, S Ray, K Struble, T Swan, V Miller, Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group, Clinical Pharmacology & Therapeutics, 2014, 96, 2, 162

    CrossRef

  4. 4
    Gianfranca Stornaiuolo, Vincenzo Cuniato, Gianluca Cuomo, Espedito Nocera, Giuseppina Brancaccio, Maddalena De Rosa, Agostina Pontarelli, Giovanni Grasso, Gaetano Danzi, Alessandra Grossi, Renato F. Natale, Giovanni B. Gaeta, Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections, Digestive and Liver Disease, 2014, 46, 1, 62

    CrossRef

  5. 5
    E. Sagnelli, T. Santantonio, N. Coppola, M. Fasano, M. Pisaturo, C. Sagnelli, Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment, Infection, 2014, 42, 4, 601

    CrossRef

  6. 6
    Suraj A. Sharma, Jordan J. Feld, Acute Hepatitis C: Management in the Rapidly Evolving World of HCV, Current Gastroenterology Reports, 2014, 16, 2

    CrossRef

  7. 7
    Masaru Enomoto, Hiroyasu Morikawa, Yoshiki Murakami, Akihiro Tamori, Norifumi Kawada, Adjuvant epoetin-β with peginterferon-α and ribavirin in Japanese ribavirin-intolerant relapsed patients with chronic hepatitis C genotype 2, Hepatology Research, 2014, 44, 9
  8. You have free access to this content8
    Hawwa Alao, T. Jake Liang, Alternative interferons and immunomodulators in the treatment of hepatitis C, Liver International, 2014, 34,
  9. 9
    Narendranath Epperla, Fergus E. McKiernan, An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosis, Skeletal Radiology, 2014, 43, 9, 1313

    CrossRef

  10. 10
    Myrna Adianti, Chie Aoki, Mari Komoto, Lin Deng, Ikuo Shoji, Tutik Sri Wahyuni, Maria Inge Lusida, Soetjipto, Hiroyuki Fuchino, Nobuo Kawahara, Hak Hotta, Anti-hepatitis C virus compounds obtained from Glycyrrhiza uralensis and other Glycyrrhiza species, Microbiology and Immunology, 2014, 58, 3
  11. 11
    P. V. Aka, M. H. Kuniholm, R. M. Pfeiffer, A. S. Wang, W. Tang, S. Chen, J. Astemborski, M. Plankey, M. C. Villacres, M. G. Peters, S. Desai, E. C. Seaberg, B. R. Edlin, H. D. Strickler, D. L. Thomas, L. Prokunina-Olsson, G. B. Sharp, T. R. O'Brien, Association of the IFNL4- G Allele With Impaired Spontaneous Clearance of Hepatitis C Virus, Journal of Infectious Diseases, 2014, 209, 3, 350

    CrossRef

  12. 12
    Tiziana Vescovo, Giulia Refolo, Alessandra Romagnoli, Fabiola Ciccosanti, Marco Corazzari, Tonino Alonzi, Gian Maria Fimia, Autophagy in HCV Infection: Keeping Fat and Inflammation at Bay, BioMed Research International, 2014, 2014, 1

    CrossRef

  13. 13
    Chung-Feng Huang, Ming-Lun Yeh, Pei-Chien Tsai, Meng-Hsuan Hsieh, Hua-Ling Yang, Ming-Yen Hsieh, Jeng-Fu Yang, Zu-Yau Lin, Shinn-Cherng Chen, Liang-Yen Wang, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu, Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication, Journal of Hepatology, 2014, 61, 1, 67

    CrossRef

  14. 14
    B. P. X. Grady, M. Prins, S. Rebers, R. Molenkamp, R. B. Geskus, J. Schinkel, BMI, male sex and IL28B genotype associated with persistently high hepatitis C virus RNA levels among chronically infected drug users up to 23 years following seroconversion, Journal of Viral Hepatitis, 2014, 21, 10
  15. 15
    Livia Maria Gonçalves Rossi, Paula Rahal, Challenges in molecular epidemiology of hepatitis C virus, Journal of Clinical Virology, 2014, 60, 2, 174

    CrossRef

  16. 16
    G. Sulis, I. El Hamad, M. Fabiani, S. Rusconi, F. Maggiolo, G. Guaraldi, G. Bozzi, C. Bernardini, M. Lichtner, C. Stentarelli, L. Carenzi, D. Francisci, A. Saracino, F. Castelli, Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000–2010, Infection, 2014, 42, 5, 859

    CrossRef

  17. 17
    Stéphane Chevaliez, Alexandre Soulier, Lila Poiteau, Magali Bouvier-Alias, Jean-Michel Pawlotsky, Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C, Journal of Clinical Virology, 2014, 61, 1, 145

    CrossRef

  18. 18
    Andréa Monteiro Tarragô, Allyson Guimarães da Costa, João Paulo Diniz Pimentel, Samara Tatielle Monteiro Gomes, Felipe Bonfim Freitas, Pritesh Lalwani, Ana Ruth S. de Araújo, Flamir da Silva Victória, Marilú Barbieri Victória, Antônio Carlos Rosário Vallinoto, Aya Sadahiro, Andréa Teixeira-Carvalho, Olindo Assis Martins-Filho, Adriana Malheiro, Combined impact of hepatitis C virus genotype 1 and interleukin-6 and tumor necrosis factor-α polymorphisms on serum levels of pro-inflammatory cytokines in Brazilian HCV-infected patients, Human Immunology, 2014,

    CrossRef

  19. 19
    V. Saxena, A. Monto, N. Terrault, Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals – authors’ reply, Alimentary Pharmacology & Therapeutics, 2014, 39, 12
  20. 20
    Andrea Galli, Jens Bukh, Comparative analysis of the molecular mechanisms of recombination in hepatitis C virus, Trends in Microbiology, 2014, 22, 6, 354

    CrossRef

  21. 21
    Blaire E. Burman, Paul Y. Kwo, Kris V. Kowdley, Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity, Hepatology International, 2014, 8, 3, 352

    CrossRef

  22. 22
    S. Lunemann, D. F. G. Malone, J. Hengst, K. Port, J. Grabowski, K. Deterding, A. Markova, B. Bremer, V. Schlaphoff, M. Cornberg, M. P. Manns, J. K. Sandberg, H.-G. Ljunggren, N. K. Bjorkstrom, H. Wedemeyer, Compromised Function of Natural Killer Cells in Acute and Chronic Viral Hepatitis, Journal of Infectious Diseases, 2014, 209, 9, 1362

    CrossRef

  23. 23
    Pankaj Puri, Anil C. Anand, Vivek A. Saraswat, Subrat K. Acharya, Radha K. Dhiman, Rakesh Aggarwal, Shivram P. Singh, Deepak Amarapurkar, Anil Arora, Mohinish Chhabra, Kamal Chetri, Gourdas Choudhuri, Vinod K. Dixit, Ajay Duseja, Ajay K. Jain, Dharmesh Kapoorz, Premashis Kar, Abraham Koshy, Ashish Kumar, Kaushal Madan, Sri P. Misra, Mohan V.G. Prasad, Aabha Nagral, Amarendra S. Puri, R. Jeyamani, Sanjiv Saigal, Shiv K. Sarin, Samir Shah, P.K. Sharma, Ajit Sood, Sandeep Thareja, Manav Wadhawan, Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India, Journal of Clinical and Experimental Hepatology, 2014, 4, 2, 106

    CrossRef

  24. 24
    Kian Bichoupan, Valerie Martel-Laferriere, David Sachs, Michel Ng, Emily A. Schonfeld, Alexis Pappas, James Crismale, Alicia Stivala, Viktoriya Khaitova, Donald Gardenier, Michael Linderman, Ponni V. Perumalswami, Thomas D. Schiano, Joseph A. Odin, Lawrence Liu, Alan J. Moskowitz, Douglas T. Dieterich, Andrea D. Branch, Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response, Hepatology, 2014, 60, 3
  25. 25
    E.-I. Pecheur, Curcumin against hepatitis C virus infection: spicing up antiviral therapies with 'nutraceuticals'?, Gut, 2014, 63, 7, 1035

    CrossRef

  26. 26
    Hugh Adler, John S Lambert, Daclatasvir for the treatment of hepatitis C virus infection, Expert Review of Gastroenterology & Hepatology, 2014, 8, 7, 725

    CrossRef

  27. 27
    Jacqueline K Flynn, Rachel Sacks-Davis, Peter Higgs, Campbell Aitken, Sarah Moneer, Vijay Suppiah, Lilly Tracy, Rosemary Ffrench, Scott Bowden, Heidi Drummer, Jacob George, Mandvi Bharadwaj, Margaret Hellard, Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users, Hepatitis Monthly, 2014, 14, 1

    CrossRef

  28. 28
    Carlos Machain-Williams, Lourdes Talavera-Aguilar, Rosa Carmina Cetina-Trejo, Jaquelin Carrillo-Navarrete, Nubia Rivero-Cárdenas, Ma. Isabel Salazar, José Arturo Farfán-Ale, Fernando I. Puerto, María Eugenia Castro-Mussot, Detection of Hepatitis C Virus Coinfection in Patients with Dengue Diagnosis, BioMed Research International, 2014, 2014, 1

    CrossRef

  29. You have free access to this content29
    B. Maasoumy, B. Cobb, B. Bremer, K. Luk, P. Halfon, S. Aslam, M. P. Manns, M. Cornberg, H. Wedemeyer, Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir, Alimentary Pharmacology & Therapeutics, 2014, 39, 1
  30. 30
    Paul M. Scola, Alan Xiangdong Wang, Andrew C. Good, Li-Qiang Sun, Keith D. Combrink, Jeffrey A. Campbell, Jie Chen, Yong Tu, Ny Sin, Brian L. Venables, Sing-Yuen Sit, Yan Chen, Anthony Cocuzza, Donna M. Bilder, Stanley D’Andrea, Barbara Zheng, Piyasena Hewawasam, Min Ding, Jan Thuring, Jianqing Li, Dennis Hernandez, Fei Yu, Paul Falk, Guangzhi Zhai, Amy K. Sheaffer, Chaoqun Chen, Min S. Lee, Diana Barry, Jay O. Knipe, Wenying Li, Yong-Hae Han, Susan Jenkins, Christoph Gesenberg, Qi Gao, Michael W. Sinz, Kenneth S. Santone, Tatyana Zvyaga, Ramkumar Rajamani, Herbert E. Klei, Richard J. Colonno, Dennis M. Grasela, Eric Hughes, Caly Chien, Stephen Adams, Paul C. Levesque, Danshi Li, Jialong Zhu, Nicholas A. Meanwell, Fiona McPhee, Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection, Journal of Medicinal Chemistry, 2014, 57, 5, 1708

    CrossRef

  31. 31
    D S Campo, P Skums, Z Dimitrova, G Vaughan, J C Forbi, C G Teo, Y Khudyakov, D T-Y Lau, Drug Resistance of a Viral Population and Its Individual Intrahost Variants During the First 48 Hours of Therapy, Clinical Pharmacology & Therapeutics, 2014, 95, 6, 627

    CrossRef

  32. 32
    K. M. Rose, Editorial Commentary: Determining the Effect of Hepatitis C on Mortality: Sorting the Signal From the Noise, Clinical Infectious Diseases, 2014, 58, 8, 1062

    CrossRef

  33. 33
    Adrian M. Di Bisceglie, Ewa Janczweska–Kazek, François Habersetzer, Wlodzimierz Mazur, Carol Stanciu, Vicente Carreno, Coman Tanasescu, Robert Flisiak, Manuel Romero–Gomez, Alexander Fich, Vincent Bataille, Myew–Ling Toh, Marie Hennequi, Patricia Zerr, Géraldine Honnet, Geneviève Inchauspé, Delphine Agathon, Jean–Marc Limacher, Heiner Wedemeyer, Efficacy of Immunotherapy With TG4040, Peg-Interferon, and Ribavirin in a Phase 2 Study of Patients With Chronic HCV Infection, Gastroenterology, 2014, 147, 1, 119

    CrossRef

  34. 34
    Tim Mathes, Sunya-Lee Antoine, Dawid Pieper, Factors influencing adherence in Hepatitis-C infected patients: a systematic review, BMC Infectious Diseases, 2014, 14, 1, 203

    CrossRef

  35. 35
    Eun-Mee Park, Lam N. Nguyen, Yun-Sook Lim, Soon B. Hwang, Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation, FEBS Letters, 2014, 588, 9, 1813

    CrossRef

  36. 36
    Radha K. Dhiman, Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?, Journal of Clinical and Experimental Hepatology, 2014, 4, 2, 85

    CrossRef

  37. 37
    Irshad ur Rehman, Gilberto Vaughan, Michael A. Purdy, Guo-liang Xia, Joseph C. Forbi, Livia Maria Gonçalves Rossi, Sadia Butt, Muhammad Idrees, Yury E. Khudyakov, Genetic history of hepatitis C virus in Pakistan, Infection, Genetics and Evolution, 2014, 27, 318

    CrossRef

  38. 38
    A L Zignego, G L Wojcik, P Cacoub, M Visentini, M Casato, A Mangia, R Latanich, E D Charles, L Gragnani, B Terrier, V Piazzola, L B Dustin, S I Khakoo, M P Busch, G M Lauer, A Y Kim, L Alric, D L Thomas, P Duggal, Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis, Genes and Immunity, 2014,

    CrossRef

  39. 39
    A H Hashmi, N Ahmad, S Riaz, L Ali, S Siddiqi, K M Khan, A R Shakoori, A Mansoor, Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection, Genes and Immunity, 2014, 15, 6, 430

    CrossRef

  40. 40
    Jane P. Messina, Isla Humphreys, Abraham Flaxman, Anthony Brown, Graham S. Cooke, Oliver G. Pybus, Eleanor Barnes, Global distribution and prevalence of hepatitis C virus genotypes, Hepatology, 2014, 60, 3
  41. 41
    Julie Bouscaillou, Julie Champagnat, Niklas Luhmann, Elisabeth Avril, Ina Inaridze, Véronique Miollany, Koka Labartkava, Irma Kirtadze, Maia Butsashvili, George Kamkamidze, Dominique Pataut, Hepatitis C among people who inject drugs in Tbilisi, Georgia: An urgent need for prevention and treatment, International Journal of Drug Policy, 2014, 25, 5, 871

    CrossRef

  42. 42
    Ed Gane, Hepatitis C beware—the end is nigh, The Lancet, 2014,

    CrossRef

  43. 43
    A. Hill, G. Cooke, Hepatitis C can be cured globally, but at what cost?, Science, 2014, 345, 6193, 141

    CrossRef

  44. 44
    Brian L. Pearlman, Carole Ehleben, Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor, Hepatology, 2014, 59, 1
  45. 45
    Andrew S. deLemos, Raymond T. Chung, Hepatitis C treatment: an incipient therapeutic revolution, Trends in Molecular Medicine, 2014, 20, 6, 315

    CrossRef

  46. 46
    W.-C. Chiu, Y.-T. Tsan, S.-L. Tsai, C.-J. Chang, J.-D. Wang, P.-C. Chen, Hepatitis C viral infection and the risk of dementia, European Journal of Neurology, 2014, 21, 8
  47. 47
    Chung-Feng Huang, Ming-Lun Yeh, Jia-Jung Lee, Mei-Chin Chen, Chia-Yen Dai, Jee-Fu Huang, Jer-Ming Chang, Hung-Chun Chen, Shang-Jyh Hwang, Wan-Long Chuang, Ming-Lung Yu, Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics, Hepatology International, 2014, 8, 2, 224

    CrossRef

  48. 48
    Ziqing Liu, Fang Zhao, Johnny J. He, Hepatitis C virus (HCV) interaction with astrocytes: nonproductive infection and induction of IL-18, Journal of NeuroVirology, 2014, 20, 3, 278

    CrossRef

  49. 49
    Aryn A Price, Arash Grakoui, Jonathan R Honegger, Hepatitis C virus adaptations to altered CD8+T-cell immunity during pregnancy, Future Virology, 2014, 9, 4, 333

    CrossRef

  50. 50
    Gokul Swaminathan, Daniel Pascual, Germaine Rival, Renzo Perales-Linares, Julio Martin-Garcia, Sonia Navas-Martin, Hepatitis C virus core protein enhances HIV-1 replication in human macrophages through TLR2, JNK, and MEK1/2-dependent upregulation of TNF-α and IL-6, FEBS Letters, 2014, 588, 18, 3501

    CrossRef

  51. 51
    Maria Buti, Rafael Esteban, Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’, Expert Review of Gastroenterology & Hepatology, 2014, 1

    CrossRef

  52. 52
    Shalimar, Hepatitis C Virus Genotype 3: Hope for Nonresponders and Patients With Cirrhosis, Journal of Clinical and Experimental Hepatology, 2014, 4, 2, 179

    CrossRef

  53. 53
    M Carrozzo, Hepatitis C virus: a silent killer relevant to dentistry, Oral Diseases, 2014, 20, 5
  54. 54
    Iara Fabricia Kretzer, Andrea do Livramento, Joel da Cunha, Sabrina Gonçalves, Iraci Tosin, Celso Spada, Aricio Treitinger, Hepatitis C Worldwide and in Brazil: Silent Epidemic—Data on Disease including Incidence, Transmission, Prevention, and Treatment, The Scientific World Journal, 2014, 2014, 1

    CrossRef

  55. 55
    Bharti Mehta, Vijay Kumar Dharma, Sumit Chawla, Harashish Jindal, Bhumika Bhatt, Hepatitis C: Is a vaccine the solution?, Human vaccines & immunotherapeutics, 2014, 10, 2, 417

    CrossRef

  56. 56
    Charles M. Rice, Mohsan Saeed, Hepatitis C: Treatment triumphs, Nature, 2014, 510, 7503, 43

    CrossRef

  57. 57
    Ming-Lung Yu, Chia-Yen Dai, Chung-Feng Huang, Jia-Jung Lee, Ming-Lun Yeh, Shih-Meng Yeh, Hsing-Tao Kuo, Jee-Fu Huang, Jer-Ming Chang, Hung-Chun Chen, Suh-Hang Hank Juo, Shang-Jyh Hwang, Wan-Long Chuang, High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients, Journal of Hepatology, 2014, 60, 2, 253

    CrossRef

  58. 58
    Benjamin Heidrich, Ahmet Cetindere, Mustafa Beyaz, Jona T. Stahmeyer, Michael M. Basaran, Boris Braynis, Regina Raupach, Birgit Bremer, Michael P. Manns, Heiner Wedemeyer, Murat Bastürk, High prevalence of hepatitis markers in immigrant populations, European Journal of Gastroenterology & Hepatology, 2014, 26, 10, 1090

    CrossRef

  59. You have free access to this content59
    P. Bruggmann, T. Berg, A. L. H. Øvrehus, C. Moreno, C. E. Brandão Mello, F. Roudot-Thoraval, R. T. Marinho, M. Sherman, S. D. Ryder, J. Sperl, U. Akarca, İ. Balık, F. Bihl, M. Bilodeau, A. J. Blasco, M. Buti, F. Calinas, J. L. Calleja, H. Cheinquer, P. B. Christensen, M. Clausen, H. S. M. Coelho, M. Cornberg, M. E. Cramp, G. J. Dore, W. Doss, A. S. Duberg, M. H. El-Sayed, G. Ergör, G. Esmat, C. Estes, K. Falconer, J. Félix, M. L. G. Ferraz, P. R. Ferreira, S. Frankova, J. García-Samaniego, J. Gerstoft, J. A. Giria, F. L. Gonçales, E. Gower, M. Gschwantler, M. Guimarães Pessôa, C. Hézode, H. Hofer, P. Husa, R. Idilman, M. Kåberg, K. D. E. Kaita, A. Kautz, S. Kaymakoglu, M. Krajden, H. Krarup, W. Laleman, D. Lavanchy, P. Lázaro, P. Marotta, S. Mauss, M. C. Mendes Correa, B. Müllhaupt, R. P. Myers, F. Negro, V. Nemecek, N. Örmeci, J. Parkes, K. M. Peltekian, A. Ramji, H. Razavi, N. Reis, S. K. Roberts, W. M. Rosenberg, R. Sarmento-Castro, C. Sarrazin, D. Semela, G. E. Shiha, W. Sievert, P. Stärkel, R. E. Stauber, A. J. Thompson, P. Urbanek, I. Thiel, H. Vlierberghe, D. Vandijck, W. Vogel, I. Waked, H. Wedemeyer, N. Weis, J. Wiegand, A. Yosry, A. Zekry, P. Damme, S. Aleman, S. J. Hindman, Historical epidemiology of hepatitis C virus (HCV) in selected countries, Journal of Viral Hepatitis, 2014, 21,
  60. 60
    Jintanat Ananworanich, Anchalee Avihingsanon, HIV and Noncommunicable Diseases, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2014, 67, S99

    CrossRef

  61. 61
    Benjamin Maasoumy, Birgit Bremer, Regina Raupach, Patrick Lehmann, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer, How to Interpret Borderline HCV Antibody Test Results: A Comparative Study Investigating Four Different Anti-HCV Assays, Viral Immunology, 2014, 27, 1, 7

    CrossRef

  62. 62
    Sumeet K. Asrani, Gary L. Davis, Impact of Birth Cohort Screening for Hepatitis C, Current Gastroenterology Reports, 2014, 16, 4

    CrossRef

  63. 63
    Lai Wei, Anna S.F. Lok, Impact of New Hepatitis C Treatments in Different Regions of the World, Gastroenterology, 2014, 146, 5, 1145

    CrossRef

  64. 64
    Masaru Enomoto, Akihiro Tamori, Yoshiki Murakami, Norifumi Kawada, Interferon-α/β for treatment of chronic hepatitis C infection in the era of direct-acting antiviral agents, Hepatology Research, 2014, 44, 4
  65. 65
    Madeline Odigie, Anu Osinusi, Lisa Barrett, Kerry Townsend, Honghui Wang, Anthony F. Suffredini, Henry Masur, Michael A. Polis, Shyam Kottilil, Interleukin-23 Promotes Interferon-α Responsiveness in Hepatitis C Virus/HIV-Coinfected Patients, AIDS Research and Human Retroviruses, 2014, 30, 8, 775

    CrossRef

  66. 66
    Joseph C. Forbi, David S. Campo, Michael A. Purdy, Zoya E. Dimitrova, Pavel Skums, Guo-liang Xia, Lili T. Punkova, Lilia M. Ganova-Raeva, Gilberto Vaughan, Yousr Ben-Ayed, William M. Switzer, Yury E. Khudyakov, Intra-host diversity and evolution of hepatitis C virus endemic to Côte d'Ivoire, Journal of Medical Virology, 2014, 86, 5
  67. 67
    Nicolas Goossens, Francesco Negro, Is genotype 3 of the hepatitis C virus the new villain?, Hepatology, 2014, 59, 6
  68. 68
    KASL clinical practice guidelines: Management of Hepatitis C, Clinical and Molecular Hepatology, 2014, 20, 2, 89

    CrossRef

  69. 69
    Benjamin Maasoumy, Kerstin Port, Katja Deterding, Christoph Höner zu Siederdissen, Antoaneta A. Markova, Magdalena Rogalska-Taranta, Michael P. Manns, Heiner Wedemeyer, Markus Cornberg, Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease, European Journal of Gastroenterology & Hepatology, 2014, 26, 8, 836

    CrossRef

  70. 70
    G Ahlén, F Holmström, A Gibbs, M Alheim, L Frelin, Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination, Gene Therapy, 2014, 21, 8, 739

    CrossRef

  71. 71
    Luydson Richardson Silva Vasconcelos, Patricia Moura, Rodrigo Feliciano do Carmo, Luciano Beltrão Pereira, Maria do Socorro de Mendonça Cavalcanti, Dayse Celia Barbosa Lins Aroucha, Rosa Amália Dutra, Leila Maria Moreira Beltrão Pereira, Low IL10 serum levels as key factor for predicting the sustained virological response to IFNα/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype, Human Immunology, 2014, 75, 8, 895

    CrossRef

  72. 72
    Paul Ravi Waldron, Mark Holodniy, MicroRNA and hepatitis C virus- challenges in investigation and translation: a review of the literature, Diagnostic Microbiology and Infectious Disease, 2014, 80, 1, 1

    CrossRef

  73. 73
    A. Hill, S. Khoo, J. Fortunak, B. Simmons, N. Ford, Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries, Clinical Infectious Diseases, 2014, 58, 7, 928

    CrossRef

  74. 74
    Yu Shi, Qiyong Guo, Fei Xia, Bogdan Dzyubak, Kevin J. Glaser, Qiuju Li, Jiahui Li, Richard L. Ehman, MR Elastography for the Assessment of Hepatic Fibrosis in Patients with Chronic Hepatitis B Infection: Does Histologic Necroinflammation Influence the Measurement of Hepatic Stiffness?, Radiology, 2014, 132592

    CrossRef

  75. 75
    M. Cornberg, C. Höner zu Siederdissen, B. Maasoumy, M.P. Manns, Neue direkt antivirale Medikamente zur Behandlung der chronischen Hepatitis C 2014, Der Internist, 2014, 55, 4, 390

    CrossRef

  76. 76
    W. Zhu, R. Pei, R. Jin, X. Hu, Y. Zhou, Y. Wang, C. Wu, M. Lu, X. Chen, Nuclear receptor 4 group A member 1 determines hepatitis C virus entry efficiency through the regulation of cellular receptor and apolipoprotein E expression, Journal of General Virology, 2014, 95, Pt_7, 1510

    CrossRef

  77. 77
    Huan V. Dong, Yamnia I. Cortés, Stephanie Shiau, Michael T. Yin, Osteoporosis and fractures in HIV/hepatitis C virus coinfection, AIDS, 2014, 28, 14, 2119

    CrossRef

  78. 78
    Gaeun Kim, Soon Koo Baik, Overview and recent trends of systematic reviews and meta-analyses in hepatology, Clinical and Molecular Hepatology, 2014, 20, 2, 137

    CrossRef

  79. 79
    James C. Iles, Jayna Raghwani, G.L. Abby Harrison, Jacques Pepin, Cyrille F. Djoko, Ubald Tamoufe, Matthew LeBreton, Bradley S. Schneider, Joseph N. Fair, Felix M. Tshala, Patrick K. Kayembe, Jean Jacques Muyembe, Samuel Edidi-Basepeo, Nathan D. Wolfe, Peter Simmonds, Paul Klenerman, Oliver G. Pybus, Phylogeography and epidemic history of hepatitis C virus genotype 4 in Africa, Virology, 2014, 464-465, 233

    CrossRef

  80. 80
    Andrew Aronsohn, Nancy Reau, Donald Jensen, Preparing for the uncertain yet inevitable: Off-label combinations of antiviral agents in hepatitis C virus, Hepatology, 2014, 59, 5
  81. 81
    Diego M Flichman, Jorgelina L Blejer, Beatriz I Livellara, Viviana E Re, Sonia Bartoli, Juan A Bustos, Claudia P Ansola, Susana Hidalgo, Martin E Cerda, Alicia E Levin, Adriana Huenul, Victoria Riboldi, Elena MC Treviño, Horacio J Salamone, Felix A Nuñez, Robert J Fernández, Juan F Reybaud, Rodolfo H Campos, Prevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donors, BMC Infectious Diseases, 2014, 14, 1, 218

    CrossRef

  82. 82
    Axel J Schmidt, Luis Falcato, Benedikt Zahno, Andrea Burri, Stephan Regenass, Beat Müllhaupt, Philip Bruggmann, Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection?, BMC Public Health, 2014, 14, 1, 3

    CrossRef

  83. 83
    Rooyen T Mavenyengwa, Munyaradzi Mukesi, Israel Chipare, Esra Shoombe, Prevalence of human immunodeficiency virus, syphilis, hepatitis B and C in blood donations in Namibia, BMC Public Health, 2014, 14, 1, 424

    CrossRef

  84. 84
    Seema Baid-Agrawal, Ralf Schindler, Petra Reinke, Adrienne Staedtler, Sunda Rimpler, Barbara Malik, Ulrich Frei, Thomas Berg, Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients, Journal of Hepatology, 2014, 60, 5, 928

    CrossRef

  85. 85
    Mohamed S. Abdel-Hakeem, Naglaa H. Shoukry, Protective Immunity Against Hepatitis C: Many Shades of Gray, Frontiers in Immunology, 2014, 5,

    CrossRef

  86. 86
    Marc G Ghany, Naveen Gara, QUEST for a cure for hepatitis C virus: the end is in sight, The Lancet, 2014, 384, 9941, 381

    CrossRef

  87. 87
    Gui Liu, Scott D. Holmberg, Saleem Kamili, Fujie Xu, Racial Disparities in the Proportion of Current, Unresolved Hepatitis C Virus Infections in the United States, 2003–2010, Digestive Diseases and Sciences, 2014, 59, 8, 1950

    CrossRef

  88. 88
    Victoria Belousova, Ahmed A. Abd-Rabou, Shaker A. Mousa, Recent advances and future directions in the management of hepatitis C infections, Pharmacology & Therapeutics, 2014,

    CrossRef

  89. 89
    Andrea Magri, Simone Bocchetta, Michela Emma Burlone, Rosalba Minisini, Mario Pirisi, Recent advances in HCV entry, Future Virology, 2014, 9, 2, 189

    CrossRef

  90. 90
    Jafar Khan, Mehwish Shafiq, Sameera Mushtaq, Sultan Ayaz, Riaz Ullah, Naser M. AbdEI-Salam, H. Fouad, Mohammad Abdul Wasim, Seropositivity and Coinfection of Hepatitis B and C among Patients Seeking Hospital Care in Islamabad, Pakistan, BioMed Research International, 2014, 2014, 1

    CrossRef

  91. 91
    Azin Nassiri, Simin Dashti-Khavidaki, Hossein Khalili, Mohsen Nassiri-Toosi, Alireza Abdollahi, Serum carnitine level and its associated factors in patients with chronic viral hepatitis, Future Virology, 2014, 9, 4, 373

    CrossRef

  92. 92
    Chao-Hung Hung, Yi-Chun Chiu, Tsung-Hui Hu, Chien-Hung Chen, Sheng-Nan Lu, Chao-Min Huang, Jing-Houng Wang, Chuan-Mo Lee, Significance of Vitamin D Receptor Gene Polymorphisms for Risk of Hepatocellular Carcinoma in Chronic Hepatitis C, Translational Oncology, 2014, 7, 4, 503

    CrossRef

  93. 93
    Brian Lam, Linda Henry, Zobair Younossi, Sofosbuvir (Sovaldi) for the treatment of hepatitis C, Expert Review of Clinical Pharmacology, 2014, 7, 5, 555

    CrossRef

  94. 94
    Gillian M. Keating, Asha Vaidya, Sofosbuvir: First Global Approval, Drugs, 2014, 74, 2, 273

    CrossRef

  95. 95
    Brian Latimer, Roberta Toporovski, Jian Yan, Panyupa Pankhong, Matthew P Morrow, Amir S Khan, Niranjan Y Sardesai, Seth L Welles, Jeffrey M Jacobson, David B Weiner, Michele A Kutzler, Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine, Human vaccines & immunotherapeutics, 2014, 10, 8

    CrossRef

  96. 96
    E. G. Meissner, A. Nelson, M. Marti, H. Masur, A. Osinusi, S. Kottilil, Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin, Open Forum Infectious Diseases, 2014, 1, 1, ofu013

    CrossRef

  97. 97
    Massimo Colombo, Simone Strasser, Christophe Moreno, Paulo Abrao Ferreira, Petr Urbanek, Inmaculada Fernández, Djamal Abdurakmonov, Adrian Streinu-Cercel, Anke Verheyen, Wafae Iraqi, Ralph DeMasi, Andrew Hill, Isabelle Lonjon-Domanec, Heiner Wedemeyer, Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program, Journal of Hepatology, 2014,

    CrossRef

  98. 98
    Yinghong Li, Zonggen Peng, Limei Gao, Danqing Song, Synthesis and biological evaluation of sophocarpinic acid derivatives as anti-HCV agents, Acta Pharmaceutica Sinica B, 2014, 4, 4, 307

    CrossRef

  99. 99
    Christopher Chapron, Rebecca Glen, Massimiliano La Colla, Benjamin A. Mayes, Joseph F. McCarville, Stephen Moore, Adel Moussa, Ruhul Sarkar, Maria Seifer, Ilaria Serra, Alistair Stewart, Synthesis of 2′-O,4′-C-alkylene-bridged ribonucleosides and their evaluation as inhibitors of HCV NS5B polymerase, Bioorganic & Medicinal Chemistry Letters, 2014, 24, 12, 2699

    CrossRef

  100. 100
    Shaihana Abdulrahman Almatrrouk, Anthony W Oliver, Lynne Hampson, Ian N Hampson, Targeting gap junction intercellular communication as a potential therapy for HCV-related carcinogenesis, Future Virology, 2014, 9, 7, 679

    CrossRef

  101. 101
    V. Saxena, M. M. Manos, H. S. Yee, L. Catalli, E. Wayne, R. C. Murphy, V. A. Shvachko, M. P. Pauly, J. Chua, A. Monto, N. A. Terrault, Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis, Alimentary Pharmacology & Therapeutics, 2014, 39, 10
  102. 102
    Ivo Ditah, Fausta Ditah, Pardha Devaki, Oforbuike Ewelukwa, Chobufo Ditah, Basile Njei, Henry N. Luma, Michael Charlton, The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010, Journal of Hepatology, 2014, 60, 4, 691

    CrossRef

  103. 103
    Seonaid Nolan, Viviane Dias Lima, Nadia Fairbairn, Thomas Kerr, Julio Montaner, Jason Grebely, Evan Wood, The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users, Addiction, 2014, 109, 10
  104. 104
    Nicolas Goossens, Francesco Negro, The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis C, Clinics in Liver Disease, 2014, 18, 1, 147

    CrossRef

  105. 105
    Xiao Fan, Bin Xue, Patrick T. Dolan, Douglas J. LaCount, Lukasz Kurgan, Vladimir N. Uversky, The intrinsic disorder status of the human hepatitis C virus proteome, Molecular BioSystems, 2014, 10, 6, 1345

    CrossRef

  106. 106
    Carol-Ann Eberle, Margarita Zayas, Alexey Stukalov, Andreas Pichlmair, Gualtiero Alvisi, André C. Müller, Keiryn L. Bennett, Ralf Bartenschlager, Giulio Superti-Furga, The lysine methyltransferase SMYD3 interacts with hepatitis C virus NS5A and is a negative regulator of viral particle production, Virology, 2014, 462-463, 34

    CrossRef

  107. 107
    L. Covolo, S. Bibert, F. Donato, P.-Y. Bochud, M. Lagging, F. Negro, G. Fattovich, The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection, Alimentary Pharmacology & Therapeutics, 2014, 39, 3
  108. You have free access to this content108
    H. Razavi, I. Waked, C. Sarrazin, R. P. Myers, R. Idilman, F. Calinas, W. Vogel, M. C. Mendes Correa, C. Hézode, P. Lázaro, U. Akarca, S. Aleman, İ. Balık, T. Berg, F. Bihl, M. Bilodeau, A. J. Blasco, C. E. Brandão Mello, P. Bruggmann, M. Buti, J. L. Calleja, H. Cheinquer, P. B. Christensen, M. Clausen, H. S. M. Coelho, M. E. Cramp, G. J. Dore, W. Doss, A. S. Duberg, M. H. El-Sayed, G. Ergör, G. Esmat, K. Falconer, J. Félix, M. L. G. Ferraz, P. R. Ferreira, S. Frankova, J. García-Samaniego, J. Gerstoft, J. A. Giria, F. L. Gonçales, E. Gower, M. Gschwantler, M. Guimarães Pessôa, S. J. Hindman, H. Hofer, P. Husa, M. Kåberg, K. D. E. Kaita, A. Kautz, S. Kaymakoglu, M. Krajden, H. Krarup, W. Laleman, D. Lavanchy, R. T. Marinho, P. Marotta, S. Mauss, C. Moreno, K. Murphy, F. Negro, V. Nemecek, N. Örmeci, A. L. H. Øvrehus, J. Parkes, K. Pasini, K. M. Peltekian, A. Ramji, N. Reis, S. K. Roberts, W. M. Rosenberg, F. Roudot-Thoraval, S. D. Ryder, R. Sarmento-Castro, D. Semela, M. Sherman, G. E. Shiha, W. Sievert, J. Sperl, P. Stärkel, R. E. Stauber, A. J. Thompson, P. Urbanek, P. Damme, I. Thiel, H. Vlierberghe, D. Vandijck, H. Wedemeyer, N. Weis, J. Wiegand, A. Yosry, A. Zekry, M. Cornberg, B. Müllhaupt, C. Estes, The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm, Journal of Viral Hepatitis, 2014, 21,
  109. 109
    Vincenza Conteduca, Domenico Sansonno, Sabino Russi, Fabio Pavone, Franco Dammacco, Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents, Journal of Infection, 2014, 68, 1, 1

    CrossRef

  110. 110
    Pablo Barreiro, Jose Vicente Fernandez-Montero, Carmen de Mendoza, Pablo Labarga, Vincent Soriano, Towards hepatitis C eradication from the HIV-infected population, Antiviral Research, 2014, 105, 1

    CrossRef

  111. 111
    Channa R. Jayasekera, Michele Barry, Lewis R. Roberts, Mindie H. Nguyen, Treating Hepatitis C in Lower-Income Countries, New England Journal of Medicine, 2014, 370, 20, 1869

    CrossRef

  112. 112
    Fabio Conti, Giovanni Vitale, Pietro Andreone, Treating hepatitis C in the elderly: the future is near?, Expert Opinion on Pharmacotherapy, 2014, 1

    CrossRef

  113. 113
    Ching-I Huang, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Ming-Lun Yeh, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Liang-Yen Wang, Ming-Lung Yu, Wan-Long Chuang, Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection, Journal of Gastroenterology and Hepatology, 2014, 29, 5
  114. 114
    Anil C. Anand, Treatment of chronic hepatitis C: What is new?, Apollo Medicine, 2014, 11, 2, 93

    CrossRef

  115. 115
    Jordan J. Feld, Kris V. Kowdley, Eoin Coakley, Samuel Sigal, David R. Nelson, Darrell Crawford, Ola Weiland, Humberto Aguilar, Junyuan Xiong, Tami Pilot-Matias, Barbara DaSilva-Tillmann, Lois Larsen, Thomas Podsadecki, Barry Bernstein, Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin, New England Journal of Medicine, 2014, 370, 17, 1594

    CrossRef

  116. 116
    Alia A. Al-Tayyib, Hanne Thiede, Richard D. Burt, Stephen Koester, Unmet Health Care Needs and Hepatitis C Infection Among Persons Who Inject Drugs in Denver and Seattle, 2009, Prevention Science, 2014,

    CrossRef

  117. 117
    L. Benova, Y. A. Mohamoud, C. Calvert, L. J. Abu-Raddad, Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis, Clinical Infectious Diseases, 2014, 59, 6, 765

    CrossRef

  118. 118
    Benoit Visseaux, Lucile Larrouy, Ruxandra Calin, Christine Katlama, Thierry Poynard, Vlad Ratziu, Vincent Thibault, Anti-hepatitis C virus antibody detection in oral fluid: Influence of human immunodeficiency virus co-infection, Journal of Clinical Virology, 2013, 58, 2, 385

    CrossRef

  119. 119
    Anuoluwapo Osinusi, Susanna Naggie, Boceprevir for HCV in patients with HIV: where next?, The Lancet Infectious Diseases, 2013, 13, 7, 563

    CrossRef

  120. 120
    T. Jake Liang, Marc G. Ghany, Current and Future Therapies for Hepatitis C Virus Infection, New England Journal of Medicine, 2013, 368, 20, 1907

    CrossRef

  121. 121
    Ana Ruth Araújo, Vanessa Peruhype-Magalhães, Jordana Grazziela Alves Coelho-dos-Reis, Laura Patrícia Viana Chaves, Tatiane Amábili de Lima, João Paulo Diniz Pimentel, Lúcia de Paula, Carlos Maurício de Almeida, Andréa Monteiro Tarragô, Adriana Tateno, José Eduardo Levi, Andrea Teixeira-Carvalho, Olindo de Assis Martins-Filho, Edson da Fonseca Lira, Kátia Luz Torres, Sinésio Talhari, Adriana Malheiro, Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-α2A and ribavirin therapy in patients with chronic hepatitis C, Immunology Letters, 2013, 154, 1-2, 61

    CrossRef

  122. 122
    Seyed-Moayed Alavian, Alireza Mirahmadizadeh, Mehdi Javanbakht, Ali Keshtkaran, Alireza Heidari, Atefeh Mashayekhi, Shima Salimi, Mohammad Hadian, Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users, Hepatitis Monthly, 2013, 13, 8

    CrossRef

  123. 123
    David L Thomas, Global control of hepatitis C: where challenge meets opportunity, Nature Medicine, 2013, 19, 7, 850

    CrossRef

  124. 124
    Tatsuo Kanda, Osamu Yokosuka, Masao Omata, Hepatitis C Virus and Hepatocellular Carcinoma, Biology, 2013, 2, 1, 304

    CrossRef

  125. 125
    Peter Liehl, Vanessa Zuzarte-Luís, Jennie Chan, Thomas Zillinger, Fernanda Baptista, Daniel Carapau, Madlen Konert, Kirsten K Hanson, Céline Carret, Caroline Lassnig, Mathias Müller, Ulrich Kalinke, Mohsan Saeed, Angelo Ferreira Chora, Douglas T Golenbock, Birgit Strobl, Miguel Prudêncio, Luis P Coelho, Stefan H Kappe, Giulio Superti-Furga, Andreas Pichlmair, Ana M Vigário, Charles M Rice, Katherine A Fitzgerald, Winfried Barchet, Maria M Mota, Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection, Nature Medicine, 2013, 20, 1, 47

    CrossRef

  126. 126
    Sarah Larney, Hannah Kopinski, Curt G. Beckwith, Nickolas D. Zaller, Don Des Jarlais, Holly Hagan, Josiah D. Rich, Brenda J. Bergh, Louisa Degenhardt, Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis, Hepatology, 2013, 58, 4
  127. 127
    Jorge T. Insua, Is There a Need for Cluster Hepatitis B and C Epidemiological Studies in the Region?: Yes, Current Hepatitis Reports, 2013, 12, 4, 288

    CrossRef

  128. 128
    Daryl Tan, Soo Yong Tan, Soon Thye Lim, Seok Jin Kim, Won-Seog Kim, Ranjana Advani, Yok-Lam Kwong, Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines, The Lancet Oncology, 2013, 14, 12, e548

    CrossRef

  129. 129
    Jannie Pedersen, Thomas H.R. Carlsen, Jannick Prentoe, Santseharay Ramirez, Tanja B. Jensen, Xavier Forns, Harvey Alter, Steven K.H. Foung, Mansun Law, Judith Gottwein, Nina Weis, Jens Bukh, Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies, Hepatology, 2013, 58, 5
  130. 130
    Khayriyyah Mohd Hanafiah, Mary Garcia, David Anderson, Point-of-care testing and the control of infectious diseases, Biomarkers in Medicine, 2013, 7, 3, 333

    CrossRef

  131. 131
    Amy J. Harzke, Regional and global summary estimates of antibody to hepatitis C virus prevalence in detainee populations: Seeing the forest and the trees?, Hepatology, 2013, 58, 4
  132. 132
    Isabel Najera, Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase, Current Opinion in Virology, 2013, 3, 5, 508

    CrossRef

  133. 133
    Chung-Feng Huang, Wan-Long Chuang, Ming-Lung Yu, The Evolution of HCV Treatment in Taiwan, Current Hepatitis Reports, 2013, 12, 3, 143

    CrossRef

  134. 134
    Mohamed A Daw, Hana A Elasifer, Aghnaya A Dau, Mohamed Agnan, The role of hepatitis C virus genotyping in evaluating the efficacy of INF-based therapy used in treating hepatitis C infected patients in Libya, Virology Discovery, 2013, 1, 1, 3

    CrossRef

  135. 135
    Cody A. Chastain, Susanna Naggie, Treatment of Genotype 1 HCV Infection in the HIV Coinfected Patient in 2014, Current HIV/AIDS Reports, 2013, 10, 4, 408

    CrossRef

  136. 136
    Chao-Long Chen, Catherine S. Kabiling, Allan M. Concejero, Why does living donor liver transplantation flourish in Asia?, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 12, 746

    CrossRef

  137. 137
    Verónica Saludes, Irene Latorre, Andreas Meyerhans, Juana Díez, MicroRNAs in Human Microbial Infections and Disease Outcomes,